非小细胞肺癌-话题@MedSci

#非小细胞肺癌#

62篇内容 | 7585人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2230002, encodeId=94042230002f5, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=c2401199e57c' target=_blank style='color:#2F92EE;'>#特立妥珠单抗#</a>, objectTitle=靶向MET的抗体偶联药来了，维汀-特立妥珠单抗治疗肺癌实现46.2%患者的病灶大幅度缩小！, objectType=article, longId=845275, objectId=389e8452e590, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202401009/1728451122202_8538692.jpg, objectUrl=/article/show_article.do?id=389e8452e590, replyNumber=0, likeNumber=69, createdTime=16小时前, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=389e8452e590, moduleTitle=靶向MET的抗体偶联药来了，维汀-特立妥珠单抗治疗肺癌实现46.2%患者的病灶大幅度缩小！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=389e8452e590)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2228159, encodeId=0bcd2228159e6, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=5c2b36548e3' target=_blank style='color:#2F92EE;'>#卡马替尼#</a>, objectTitle=颅内转移的MET ex14跳变非小细胞肺癌患者在克唑替尼治疗进展后获益卡马替尼, objectType=article, longId=844990, objectId=a3fd8449903b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240927/1727432425497_8538692.jpg, objectUrl=/article/show_article.do?id=a3fd8449903b, replyNumber=0, likeNumber=81, createdTime=2024-09-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a3fd8449903b, moduleTitle=颅内转移的MET ex14跳变非小细胞肺癌患者在克唑替尼治疗进展后获益卡马替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3fd8449903b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2228219, encodeId=26b622282190e, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=9f15110e82fc' target=_blank style='color:#2F92EE;'>#软脑膜转移#</a> <a href='/topic/show?id=f5141196582a' target=_blank style='color:#2F92EE;'>#呋莫替尼#</a>, objectTitle=可赞许！高剂量靶向药呋莫替尼治疗EGFR阳性脑膜转移的肺癌！, objectType=article, longId=844902, objectId=383b844902fe, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240708/1720420864050_92910.png, objectUrl=/article/show_article.do?id=383b844902fe, replyNumber=0, likeNumber=69, createdTime=2024-09-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=383b844902fe, moduleTitle=可赞许！高剂量靶向药呋莫替尼治疗EGFR阳性脑膜转移的肺癌！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=383b844902fe)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2227913, encodeId=92b9222e91339, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=f38743453f7' target=_blank style='color:#2F92EE;'>#多西他赛#</a> <a href='/topic/show?id=7682119581e5' target=_blank style='color:#2F92EE;'>#普那布林#</a>, objectTitle=《柳叶刀》子刊：3年生存率翻倍！非小细胞肺癌二三线治疗新选择, objectType=article, longId=844838, objectId=c666844838aa, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240620/1718871228312_5579292.png, objectUrl=/article/show_article.do?id=c666844838aa, replyNumber=0, likeNumber=19, createdTime=2024-09-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c666844838aa, moduleTitle=《柳叶刀》子刊：3年生存率翻倍！非小细胞肺癌二三线治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c666844838aa)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226850, encodeId=8572222685066, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=KRAS G12C突变非小细胞肺癌患者的临床、病理和分子特征, objectType=article, longId=844002, objectId=b959844002ce, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240628/1719567809676_92910.png, objectUrl=/article/show_article.do?id=b959844002ce, replyNumber=0, likeNumber=0, createdTime=2024-09-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b959844002ce, moduleTitle=KRAS G12C突变非小细胞肺癌患者的临床、病理和分子特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b959844002ce)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226977, encodeId=e2e422269e742, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=329c2e376fa' target=_blank style='color:#2F92EE;'>#信迪利单抗#</a>, objectTitle=EGFR 19del/T790M/C797S顺式突变耐药非小细胞肺癌获益信迪利单抗/抗VEGF/化疗, objectType=article, longId=844131, objectId=26c68441315f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240920/1726800373067_8538692.png, objectUrl=/article/show_article.do?id=26c68441315f, replyNumber=0, likeNumber=27, createdTime=2024-09-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=26c68441315f, moduleTitle=EGFR 19del/T790M/C797S顺式突变耐药非小细胞肺癌获益信迪利单抗/抗VEGF/化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26c68441315f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226670, encodeId=d34d22266e049, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=e62011236077' target=_blank style='color:#2F92EE;'>#洛拉替尼#</a>, objectTitle=靶向药不良反应大，ALK三代药洛拉替尼剂量调整降低不适且不影响生存期！, objectType=article, longId=842391, objectId=829d84239158, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240914/1726306659945_8538692.png, objectUrl=/article/show_article.do?id=829d84239158, replyNumber=0, likeNumber=29, createdTime=2024-09-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=829d84239158, moduleTitle=靶向药不良反应大，ALK三代药洛拉替尼剂量调整降低不适且不影响生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=829d84239158)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226420, encodeId=3846222642039, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=648d118539fc' target=_blank style='color:#2F92EE;'>#WCLC 2024#</a> <a href='/topic/show?id=f0d71192319a' target=_blank style='color:#2F92EE;'>#EGFR与MET双重阻断#</a>, objectTitle=WCLC 2024 | 对话David Lee：探索EGFR与MET双重阻断在非小细胞肺癌治疗中的新突破, objectType=article, longId=843820, objectId=8f1a8438208d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240918/1726644911881_92910.png, objectUrl=/article/show_article.do?id=8f1a8438208d, replyNumber=0, likeNumber=0, createdTime=2024-09-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8f1a8438208d, moduleTitle=WCLC 2024 | 对话David Lee：探索EGFR与MET双重阻断在非小细胞肺癌治疗中的新突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f1a8438208d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226368, encodeId=1ea722263685a, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=567041e8055' target=_blank style='color:#2F92EE;'>#基因治疗#</a> <a href='/topic/show?id=648d118539fc' target=_blank style='color:#2F92EE;'>#WCLC 2024#</a> <a href='/topic/show?id=60321192098d' target=_blank style='color:#2F92EE;'>#STK11/KEAP1突变#</a>, objectTitle=WCLC 2024 | 对话Arushi Saini博士：STK11/KEAP1共突变NSCLC患者基因治疗新视角, objectType=article, longId=843748, objectId=12aa843e4801, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240918/1726631783547_92910.png, objectUrl=/article/show_article.do?id=12aa843e4801, replyNumber=0, likeNumber=25, createdTime=2024-09-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=12aa843e4801, moduleTitle=WCLC 2024 | 对话Arushi Saini博士：STK11/KEAP1共突变NSCLC患者基因治疗新视角, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12aa843e4801)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226097, encodeId=6823222609eea, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=e4cb11e4516f' target=_blank style='color:#2F92EE;'>#RBM10#</a>, objectTitle=RBM10突变非小细胞肺癌患者的预后差，且与EGFR-TKI的晚期耐药相关, objectType=article, longId=843511, objectId=ea98843511b9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240905/1725521610942_8538692.jpg, objectUrl=/article/show_article.do?id=ea98843511b9, replyNumber=0, likeNumber=27, createdTime=2024-09-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ea98843511b9, moduleTitle=RBM10突变非小细胞肺癌患者的预后差，且与EGFR-TKI的晚期耐药相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea98843511b9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226139, encodeId=48e42226139cd, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=71d211064502' target=_blank style='color:#2F92EE;'>#STING通路#</a> <a href='/topic/show?id=c46e119165c5' target=_blank style='color:#2F92EE;'>#PD-1治疗#</a>, objectTitle=上海交大夏伟梁/陆舜Science大子刊：PTPRT缺失可通过调节STING通路在非小细胞肺癌中增强抗PD -1治疗效果, objectType=article, longId=843292, objectId=a6c8843292ea, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240701/1719800269608_92910.png, objectUrl=/article/show_article.do?id=a6c8843292ea, replyNumber=0, likeNumber=27, createdTime=2024-09-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a6c8843292ea, moduleTitle=上海交大夏伟梁/陆舜Science大子刊：PTPRT缺失可通过调节STING通路在非小细胞肺癌中增强抗PD -1治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6c8843292ea)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2225505, encodeId=33dc2225505f8, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=抗癌新药IBI351疗效数据出炉，近50%的KRAS基因突变患者病灶缩小30%！, objectType=article, longId=841981, objectId=ca95841981bd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240707/1720362208683_5579292.jpg, objectUrl=/article/show_article.do?id=ca95841981bd, replyNumber=0, likeNumber=33, createdTime=2024-09-12, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ca95841981bd, moduleTitle=抗癌新药IBI351疗效数据出炉，近50%的KRAS基因突变患者病灶缩小30%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca95841981bd)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2225238, encodeId=a3462225238f6, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a>, objectTitle=新一代基于计算病理学的TROP2生物标志物可预测datopotamab deruxtecan TROPION-Lung01 III期临床试验中非小细胞肺癌患者的临床治疗结果, objectType=article, longId=842743, objectId=0e23842e4380, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240802/1722591216030_8538692.png, objectUrl=/article/show_article.do?id=0e23842e4380, replyNumber=0, likeNumber=26, createdTime=2024-09-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0e23842e4380, moduleTitle=新一代基于计算病理学的TROP2生物标志物可预测datopotamab deruxtecan TROPION-Lung01 III期临床试验中非小细胞肺癌患者的临床治疗结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e23842e4380)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2225241, encodeId=d4392225241cf, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a>, objectTitle=新一代基于计算病理学的TROP2生物标志物可预测datopotamab deruxtecan TROPION-Lung01 III期临床试验中非小细胞肺癌患者的临床治疗结果, objectType=article, longId=841902, objectId=9006841902f2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240911/1726018538075_8538692.png, objectUrl=/article/show_article.do?id=9006841902f2, replyNumber=0, likeNumber=5, createdTime=2024-09-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2225074, encodeId=4a9d22250e47c, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=f46311051235' target=_blank style='color:#2F92EE;'>#埃万妥单抗#</a> <a href='/topic/show?id=c64a10641526' target=_blank style='color:#2F92EE;'>#拉泽替尼#</a>, objectTitle=读书报告 | MARIPOSA研究：埃万妥单抗联合拉泽替尼一线治疗EGFR突变晚期 NSCLC, objectType=article, longId=842004, objectId=0f8b8420046e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240904/1725441132704_8538692.jpg, objectUrl=/article/show_article.do?id=0f8b8420046e, replyNumber=0, likeNumber=34, createdTime=2024-09-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0f8b8420046e, moduleTitle=读书报告 | MARIPOSA研究：埃万妥单抗联合拉泽替尼一线治疗EGFR突变晚期 NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f8b8420046e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2225066, encodeId=f9e42225066c2, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=f46311051235' target=_blank style='color:#2F92EE;'>#埃万妥单抗#</a> <a href='/topic/show?id=c64a10641526' target=_blank style='color:#2F92EE;'>#拉泽替尼#</a>, objectTitle=指南更新 | 非小细胞肺癌NCCN（2024.V9）：新增埃万妥单抗联合拉泽替尼一线治疗方案, objectType=article, longId=831329, objectId=667483132907, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240909/1725866089036_8538692.jpg, objectUrl=/article/show_article.do?id=667483132907, replyNumber=0, likeNumber=26, createdTime=2024-09-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=667483132907, moduleTitle=指南更新 | 非小细胞肺癌NCCN（2024.V9）：新增埃万妥单抗联合拉泽替尼一线治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=667483132907)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2225092, encodeId=cdb7222509203, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=c0501084e91d' target=_blank style='color:#2F92EE;'>#贝福替尼#</a>, objectTitle=连线WCLC | 凯赛携手靶向耐药新策略，重磅数据亮相2024 WCLC, objectType=article, longId=842618, objectId=e0088426180d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240709/1720503095993_8538692.jpg, objectUrl=/article/show_article.do?id=e0088426180d, replyNumber=0, likeNumber=31, createdTime=2024-09-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e0088426180d, moduleTitle=连线WCLC | 凯赛携手靶向耐药新策略，重磅数据亮相2024 WCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0088426180d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2224222, encodeId=93ed2224222bd, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=e62011236077' target=_blank style='color:#2F92EE;'>#洛拉替尼#</a>, objectTitle=专治不服！洛拉替尼让肺癌软脑膜转移病灶全消失长达2年！, objectType=article, longId=841330, objectId=32d6841330d9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240904/1725441558776_8538692.png, objectUrl=/article/show_article.do?id=32d6841330d9, replyNumber=0, likeNumber=38, createdTime=2024-09-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=32d6841330d9, moduleTitle=专治不服！洛拉替尼让肺癌软脑膜转移病灶全消失长达2年！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32d6841330d9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2224233, encodeId=f722222423320, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=a3d94e350d6' target=_blank style='color:#2F92EE;'>#尼古丁#</a> <a href='/topic/show?id=b6a7118e59c3' target=_blank style='color:#2F92EE;'>#TRIM29#</a>, objectTitle=论文解读｜Pu Xia教授团队揭示尼古丁通过TRIM29在非小细胞肺癌中上调, objectType=article, longId=835013, objectId=110183501356, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240625/1719305607152_92910.png, objectUrl=/article/show_article.do?id=110183501356, replyNumber=0, likeNumber=39, createdTime=2024-09-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=110183501356, moduleTitle=论文解读｜Pu Xia教授团队揭示尼古丁通过TRIM29在非小细胞肺癌中上调, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=110183501356)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2224160, encodeId=ec07222416012, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a>, objectTitle=先声再明与塔吉瑞签订合作协议，引进第三代ALK抑制剂, objectType=article, longId=841904, objectId=afb1841904b6, topicUrl=null, isHasObj=0, objectCover=https://msimg.bioon.com/bioon-com/20240905/1725502695130_8827638.jpg, objectUrl=/article/show_article.do?id=afb1841904b6, replyNumber=0, likeNumber=6, createdTime=2024-09-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯话题小助手

非小细胞肺癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #特立妥珠单抗#

靶向MET的抗体偶联药来了，维汀-特立妥珠单抗治疗肺癌实现46.2%患者的病灶大幅度缩小！

16小时前发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #卡马替尼#

颅内转移的MET ex14跳变非小细胞肺癌患者在克唑替尼治疗进展后获益卡马替尼

2024-09-28发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #软脑膜转移# #呋莫替尼#

可赞许！高剂量靶向药呋莫替尼治疗EGFR阳性脑膜转移的肺癌！

2024-09-28发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #多西他赛# #普那布林#

《柳叶刀》子刊：3年生存率翻倍！非小细胞肺癌二三线治疗新选择

2024-09-26发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #KRAS#

KRAS G12C突变非小细胞肺癌患者的临床、病理和分子特征

2024-09-21发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #信迪利单抗#

EGFR 19del/T790M/C797S顺式突变耐药非小细胞肺癌获益信迪利单抗/抗VEGF/化疗

2024-09-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #洛拉替尼#

靶向药不良反应大，ALK三代药洛拉替尼剂量调整降低不适且不影响生存期！

2024-09-19发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #WCLC 2024# #EGFR与MET双重阻断#

WCLC 2024 | 对话David Lee：探索EGFR与MET双重阻断在非小细胞肺癌治疗中的新突破

2024-09-18发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #基因治疗# #WCLC 2024# #STK11/KEAP1突变#

WCLC 2024 | 对话Arushi Saini博士：STK11/KEAP1共突变NSCLC患者基因治疗新视角

2024-09-18发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #RBM10#

RBM10突变非小细胞肺癌患者的预后差，且与EGFR-TKI的晚期耐药相关

2024-09-16发表于上海

梅斯管理员 (审核中...)